This article has been updated to include additional information from the complaint against Myriad Genetics filed in the US District Court for the District of South Carolina.
NEW YORK – Myriad Genetics has entered into a $9.1 million settlement agreement to resolve allegations that it improperly billed Medicare for its hereditary cancer tests, after the US Department of Justice declined to intervene in the matter.